Exclusion Criteria:
Those who donated blood or suffered blood loss ≥400 mL within 3 months
prior to Screening, donated blood or suffered blood loss ≥200 mL within
1 month prior to screening, or received blood transfusion; Allergic
constitution, including a history of severe drug/food allergy; Any
history of allergy to famitinib malate capsules or omeprazole magnesium
enteric-coated tablets; Any history of drug abuse, positive results for
alcohol, nicotine or drugs at Screening; Those who have heavy smokers
and alcoholic will not be able to prohibit smoking and alcohol during
the trial; Any history of dysphagia or any gastrointestinal disease that
affects drug absorption; Those who have any uncontrolled peptic ulcer,
colitis, pancreatitis, etc.; Those who have received any operation
within 6 months before Screening; Previous surgery affecting
gastrointestinal absorption (including gastrectomy, intestinal
resection, gastric contraction surgery, etc.);Subjects with any
clinically significant acute disease occurring within 1 month prior to
Screening; QTcF>470 msec for women or >450
msec for men; Any pre-existing chronic or severe medical history of
nervous system, cardiovascular system, urinary system, digestive system,
respiratory system, metabolism, and musculoskeletal system;
Participation in any clinical trial within 3 months before Screening;
Those who took any other drugs that affect liver metabolism within 28
days prior to taking the investigational drug; Those who took any
prescription or non-prescription drugs, any vitamin products or herbal
medicine within 14 days prior to receiving the investigational drug;
Abnormal vital signs at Screening; Clinical laboratory tests, infectious
disease screening, 12-lead electrocardiogram, abdominal B ultrasound,
X-ray or CT examination with abnormalities and clinical significance;
Consumption of grapefruit or grapefruit products, caffeine, or xanthine
foods or beverages within 48 hours prior to taking the investigational
drug; Strenuous exercise, or other factors affecting drug absorption,
distribution, metabolism, excretion, etc.; Lactating women; History of
injection needle or blood fainting, those who have difficulty in blood
collection or cannot tolerate venipuncture blood collection; Those who
cannot accept a uniform diet; Subjects with other factors unsuitable to
participate in the study considered by the researcher or subjects
withdraw from the study due to their own reasons.